menu
    • menu

    Company profile for Transposon Therapeutics

    NEW Drugs in Dev: 2
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Transposon is actively engaged in the development of nucleoside inhibitors targeting LINE-1 reverse transcriptase (NRTI) and other agents associated with LINE-1 pathology, including Protein Kinase R inhibitors (PKR). This focus is directed towards addressing neurodegenerative diseases. Notably, TPN-101, identified as their most potent inhibitor of LINE-1 reverse transcriptase, is currently undergoing investigation in two Phase...
    Transposon is actively engaged in the development of nucleoside inhibitors targeting LINE-1 reverse transcriptase (NRTI) and other agents associated with LINE-1 pathology, including Protein Kinase R inhibitors (PKR). This focus is directed towards addressing neurodegenerative diseases. Notably, TPN-101, identified as their most potent inhibitor of LINE-1 reverse transcriptase, is currently undergoing investigation in two Phase 2a clinical trials. This underscores Transposon's commitment to advancing potential treatments for neurodegenerative diseases through the development of innovative therapeutic agents.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Transposon TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Diego, CA 92122
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.transposonrx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    BePharma

    Not Confirmed

    envelop Contact Supplier

    BePharma

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Transposon Therapeutics To Study TPN-101 For Healthy Aging
    Transposon Therapeutics To Study TPN-101 For Healthy Aging

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249213/0/en/Transposon-Therapeutics-TPN-101-to-be-Studied-for-Extending-Healthy-Aging-under-ARPA-H-Award-for-up-to-22M.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share
    Transposon Gets Funding For Alzheimer’s Candidate TPN-101
    Transposon Gets Funding For Alzheimer’s Candidate TPN-101

    09 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/transposon-receives-investment-from-the-alzheimers-drug-discovery-foundation-to-support-advancement-of-tpn-101-for-the-treatment-of-alzheimers-disease-302500597.html

    PR NEWSWIRE
    09 Jul 2025
    Share Share
    TPN-101 Joins Healey Trial After C9orf72 ALS Success
    TPN-101 Joins Healey Trial After C9orf72 ALS Success

    28 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/transposon-announces-tpn-101-selected-for-inclusion-in-the-phase-23-healey-als-platform-trial-building-on-the-success-of-phase-2-study-in-c9orf72-related-als-302466319.html

    PR NEWSWIRE
    28 May 2025
    Share Share
    Transposon Acquires Portfolio of Novel Nucleoside Analogs
    Transposon Acquires Portfolio of Novel Nucleoside Analogs

    21 Nov 2024

    // CONTRACTPHARMA

    https://www.contractpharma.com//contents/view_breaking-news/2024-11-21/transposon-therapeutics-acquires-portfolio-of-novel-nucleoside-analogs/?widget=listSection

    CONTRACTPHARMA
    21 Nov 2024
    Share Share
    Transposon Expands Pipeline with Acquisition of Nucleoside Analogs
    Transposon Expands Pipeline with Acquisition of Nucleoside Analogs

    21 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/transposon-therapeutics-strengthens-and-expands-development-pipeline-with-the-acquisition-of-a-portfolio-of-novel-nucleoside-analogs-for-oncology-302312312.html

    PR NEWSWIRE
    21 Nov 2024
    Share Share
    Transposon to Present TPN-101 Data for C9orf72 ALS/FTD at ALS ONE
    Transposon to Present TPN-101 Data for C9orf72 ALS/FTD at ALS ONE

    06 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/transposon-to-present-results-from-phase-2-study-of-tpn-101-for-the-treatment-of-c9orf72-related-alsftd-at-the-7th-annual-als-one-research-symposium-302296819.html

    PR NEWSWIRE
    06 Nov 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search